GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clovis Oncology Inc (OTCPK:CLVSQ) » Definitions » ROE %

Clovis Oncology (Clovis Oncology) ROE % : 0.00% (As of Sep. 2022)


View and export this data going back to 2011. Start your Free Trial

What is Clovis Oncology ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Clovis Oncology's annualized net income for the quarter that ended in Sep. 2022 was $-224.1 Mil. Clovis Oncology's average Total Stockholders Equity over the quarter that ended in Sep. 2022 was $-392.8 Mil. Therefore, Clovis Oncology's annualized ROE % for the quarter that ended in Sep. 2022 was N/A%.

The historical rank and industry rank for Clovis Oncology's ROE % or its related term are showing as below:

CLVSQ's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -44.1
* Ranked among companies with meaningful ROE % only.

Clovis Oncology ROE % Historical Data

The historical data trend for Clovis Oncology's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clovis Oncology ROE % Chart

Clovis Oncology Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -190.33 -143.16 - - -

Clovis Oncology Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Clovis Oncology's ROE %

For the Biotechnology subindustry, Clovis Oncology's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clovis Oncology's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clovis Oncology's ROE % distribution charts can be found below:

* The bar in red indicates where Clovis Oncology's ROE % falls into.



Clovis Oncology ROE % Calculation

Clovis Oncology's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=-264.524/( (-158.748+-278.84)/ 2 )
=-264.524/-218.794
=N/A %

Clovis Oncology's annualized ROE % for the quarter that ended in Sep. 2022 is calculated as

ROE %=Net Income (Q: Sep. 2022 )/( (Total Stockholders Equity (Q: Jun. 2022 )+Total Stockholders Equity (Q: Sep. 2022 ))/ count )
=-224.056/( (-367.695+-417.886)/ 2 )
=-224.056/-392.7905
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2022) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Clovis Oncology  (OTCPK:CLVSQ) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2022 )
=Net Income/Total Stockholders Equity
=-224.056/-392.7905
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-224.056 / 122.652)*(122.652 / 369.8155)*(369.8155 / -392.7905)
=Net Margin %*Asset Turnover*Equity Multiplier
=-182.68 %*0.3317*N/A
=ROA %*Equity Multiplier
=-60.59 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2022 )
=Net Income/Total Stockholders Equity
=-224.056/-392.7905
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-224.056 / -223.916) * (-223.916 / -176.94) * (-176.94 / 122.652) * (122.652 / 369.8155) * (369.8155 / -392.7905)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0006 * 1.2655 * -144.26 % * 0.3317 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Clovis Oncology ROE % Related Terms

Thank you for viewing the detailed overview of Clovis Oncology's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clovis Oncology (Clovis Oncology) Business Description

Traded in Other Exchanges
N/A
Address
5500 Flatiron Parkway, Suite 100, Boulder, CO, USA, 80301
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.
Executives
Thomas C. Harding officer: See Remarks 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Gillian C Ivers-read officer: See Remarks C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Lindsey Rolfe officer: See remarks C/O CLOVIS ONCOLOGY, INC., 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Daniel W Muehl officer: See remarks 5 BILLERICA PARK, 101 BILLERICA AVE, NORTH BILLERCA MA 01862
Paul Edward Gross officer: See Remarks 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80302
Ronit Simantov director 1988 CHAPEL STREET, NEW HAVEN CT 06515
James C Blair director 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Patrick J Mahaffy director, officer: President and CEO C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Thorlef Spickschen director TRAUBENWEG 25, 64342 SEEHEIN-JUGENHEIM 2M 00000
Richard A. Fair director C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Robert Azelby director 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Hooks Corwin Dale officer: See remarks C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, BOULDER CO 80301
Paul H Klingenstein director 428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301
Ginger L Graham director AMYLIN PHARMACEUTICALS, INC., 885 ARAPAHOE AVENUE, BOULDER CO 80302
Brian G Atwood director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

Clovis Oncology (Clovis Oncology) Headlines